Company attributes
Other attributes
Rgenix is a clinical-stage biopharmaceutical company developing drug candidates that target key cancer pathways in cancer progression. Its proprietary technology can be applied to any kind of cancer and has yielded novel therapeutic targets for many high unmet need malignancies.
Through the discovery platform that was developed by Rgenix’s founding scientists at Rockefeller University, and now licensed to Rgenix, the company has discovered many novel cancer targets that drive tumor growth and cancer progression.
Rgenix’s product pipeline addresses cancers diagnosed in over 500,000 patients yearly in the US, including drug-resistant cancer types, these cancers result in over 250,000 deaths annually in America, with 5-year survival rates often as low as 10%-20% for patients with metastatic disease.
